AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%

Tue, 12 Feb

AUROBINDO PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

Year-on-Year Performance:

• The company's operating income during the quarter grew 21.5% on a year-on-year (YoY) basis. The expenses were up by 26.4% YoY during the same period.
• The company's operating profit increased by 3.5% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 23.7% in 3QFY18.
• Depreciation charges increased by 18.1% and finance costs increased by 152.7% YoY, respectively.
• Other income increased by 93.2% YoY during the quarter.
• Net profit for the quarter increased by 19.3% YoY. Net profit margins during the quarter declined from 13.6% in 3QFY18 to 13.3% in 3QFY19.

Quarter-on-Quarter Performance:

• The company's operating income during the quarter grew 10.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 11.1% QoQ during the same period.
• The company's operating profit declined by 10.6% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 20.2% in 2QFY18.
• Net profit for the quarter increased by 16.1% QoQ, while net profit margins increased from 12.8% in 2QFY18 to 13.3% in 3QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 607.9 to Rs 766.0, registering a Gain of Rs 158.2 or around 26.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,712.7 (down 0.1%). Over the last one year it has moved down from 14,517.2 to 13,712.7, a gain of 805 points (down 5.5%).

Overall, the S&P BSE SENSEX is up 6.1% over the year.

Current Valuations

At the current price of Rs 766.0, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 19.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.8 times.